KR102027448B1 - Hsp90 병용요법 - Google Patents

Hsp90 병용요법 Download PDF

Info

Publication number
KR102027448B1
KR102027448B1 KR1020137031561A KR20137031561A KR102027448B1 KR 102027448 B1 KR102027448 B1 KR 102027448B1 KR 1020137031561 A KR1020137031561 A KR 1020137031561A KR 20137031561 A KR20137031561 A KR 20137031561A KR 102027448 B1 KR102027448 B1 KR 102027448B1
Authority
KR
South Korea
Prior art keywords
hsp90
cancer
cells
cell
delete delete
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020137031561A
Other languages
English (en)
Korean (ko)
Other versions
KR20140059757A (ko
Inventor
가브리엘라 키오시스
Original Assignee
슬로안-케테링인스티튜트퍼캔서리서치
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 슬로안-케테링인스티튜트퍼캔서리서치 filed Critical 슬로안-케테링인스티튜트퍼캔서리서치
Publication of KR20140059757A publication Critical patent/KR20140059757A/ko
Application granted granted Critical
Publication of KR102027448B1 publication Critical patent/KR102027448B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
KR1020137031561A 2011-04-28 2012-04-27 Hsp90 병용요법 Expired - Fee Related KR102027448B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161480198P 2011-04-28 2011-04-28
US61/480,198 2011-04-28
PCT/US2012/035690 WO2012149493A2 (en) 2011-04-28 2012-04-27 Hsp90 combination therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020197028143A Division KR102196424B1 (ko) 2011-04-28 2012-04-27 Hsp90 병용요법

Publications (2)

Publication Number Publication Date
KR20140059757A KR20140059757A (ko) 2014-05-16
KR102027448B1 true KR102027448B1 (ko) 2019-10-01

Family

ID=47073116

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197028143A Expired - Fee Related KR102196424B1 (ko) 2011-04-28 2012-04-27 Hsp90 병용요법
KR1020137031561A Expired - Fee Related KR102027448B1 (ko) 2011-04-28 2012-04-27 Hsp90 병용요법

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020197028143A Expired - Fee Related KR102196424B1 (ko) 2011-04-28 2012-04-27 Hsp90 병용요법

Country Status (12)

Country Link
US (2) US20140315929A1 (enExample)
EP (1) EP2701747A4 (enExample)
JP (3) JP6363502B2 (enExample)
KR (2) KR102196424B1 (enExample)
CN (2) CN109498812A (enExample)
AU (3) AU2012249322B2 (enExample)
BR (1) BR112013027448A2 (enExample)
CA (1) CA2833390A1 (enExample)
EA (1) EA201391587A1 (enExample)
MX (1) MX2013012183A (enExample)
NZ (1) NZ618062A (enExample)
WO (1) WO2012149493A2 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102025142B1 (ko) 2011-07-08 2019-09-26 슬로안-케테링인스티튜트퍼캔서리서치 표지된 ｈｓｐ90 억제제의 용도
US20140079636A1 (en) * 2012-04-16 2014-03-20 Dinesh U. Chimmanamada Targeted therapeutics
SI2935222T1 (sl) 2012-12-21 2019-02-28 Epizyme Inc. Inhibitorji PRMT5 in njihove uporabe
WO2015089402A1 (en) * 2013-12-12 2015-06-18 The University Of Chicago Methods and compositions related to hsp90 inhibitors and breast cancer
EP3086792B1 (en) 2013-12-23 2022-10-12 Memorial Sloan-Kettering Cancer Center Methods and reagents for radiolabeling
WO2015168599A1 (en) * 2014-05-02 2015-11-05 The Wistar Institute Of Anatomy And Biology Combination therapies targeting mitochondria for cancer therapy
CA2961499A1 (en) 2014-09-17 2016-03-24 Memorial Sloan Kettering Cancer Center Hsp90-targeted inflammation and infection imaging and therapy
US10265009B2 (en) 2014-10-21 2019-04-23 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with microbiome taxonomic features
US10793907B2 (en) 2014-10-21 2020-10-06 Psomagen, Inc. Method and system for microbiome-derived diagnostics and therapeutics for endocrine system conditions
US11783914B2 (en) 2014-10-21 2023-10-10 Psomagen, Inc. Method and system for panel characterizations
US10388407B2 (en) 2014-10-21 2019-08-20 uBiome, Inc. Method and system for characterizing a headache-related condition
US10777320B2 (en) 2014-10-21 2020-09-15 Psomagen, Inc. Method and system for microbiome-derived diagnostics and therapeutics for mental health associated conditions
US10410749B2 (en) 2014-10-21 2019-09-10 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for cutaneous conditions
US9710606B2 (en) 2014-10-21 2017-07-18 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for neurological health issues
US10409955B2 (en) 2014-10-21 2019-09-10 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for locomotor system conditions
CN107075588B (zh) 2014-10-21 2023-03-21 普梭梅根公司 用于微生物组来源的诊断和治疗的方法及系统
US10346592B2 (en) 2014-10-21 2019-07-09 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for neurological health issues
US9760676B2 (en) 2014-10-21 2017-09-12 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for endocrine system conditions
US10073952B2 (en) 2014-10-21 2018-09-11 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for autoimmune system conditions
US10789334B2 (en) 2014-10-21 2020-09-29 Psomagen, Inc. Method and system for microbial pharmacogenomics
US9754080B2 (en) 2014-10-21 2017-09-05 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for cardiovascular disease conditions
US10366793B2 (en) 2014-10-21 2019-07-30 uBiome, Inc. Method and system for characterizing microorganism-related conditions
US10395777B2 (en) 2014-10-21 2019-08-27 uBiome, Inc. Method and system for characterizing microorganism-associated sleep-related conditions
US10325685B2 (en) 2014-10-21 2019-06-18 uBiome, Inc. Method and system for characterizing diet-related conditions
US10381112B2 (en) 2014-10-21 2019-08-13 uBiome, Inc. Method and system for characterizing allergy-related conditions associated with microorganisms
US10169541B2 (en) 2014-10-21 2019-01-01 uBiome, Inc. Method and systems for characterizing skin related conditions
US9758839B2 (en) 2014-10-21 2017-09-12 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with microbiome functional features
US10311973B2 (en) 2014-10-21 2019-06-04 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for autoimmune system conditions
US10357157B2 (en) 2014-10-21 2019-07-23 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for conditions associated with functional features
US10246753B2 (en) 2015-04-13 2019-04-02 uBiome, Inc. Method and system for characterizing mouth-associated conditions
AU2016250096A1 (en) * 2015-04-13 2017-11-09 Psomagen, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for conditions associated with functional features
CN106265660B (zh) * 2015-05-21 2019-08-02 中国科学院合肥物质科学研究院 A674563在携带flt3突变型基因的急性白血病中的用途
CN106349180B (zh) * 2015-07-14 2020-05-19 上海翰森生物医药科技有限公司 4,5-二苯基异噁唑衍生物及其制备方法和应用
AU2017305502B2 (en) * 2016-08-03 2024-06-20 Remd Biotherapeutics, Inc. Combination of glucagon receptor antagonists and PI3K pathway inhibitors for the treatment of cancer
WO2018144680A1 (en) 2017-02-03 2018-08-09 Lam Therapeutics, Inc. Methods for treating cancer using hsp90 inhibitors
US11491145B2 (en) 2017-06-20 2022-11-08 Madrigal Pharmaceuticals, Inc. Combination therapies comprising targeted therapeutics
CA3067572A1 (en) 2017-06-20 2018-12-27 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
JP7558167B2 (ja) 2018-12-03 2024-09-30 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム オリゴベンズアミド類似体およびがん処置におけるそれらの使用
CN109554343B (zh) * 2018-12-29 2022-04-19 吉林大学 一种适于神经元粘附与存活的涂层材料及制备方法
CN111467472B (zh) * 2020-04-21 2020-12-25 南京中医药大学 一种靶向肿瘤相关巨噬细胞的免疫调节微球制剂及其制备方法与应用
US20230218577A1 (en) * 2020-06-11 2023-07-13 The Children's Medical Center Corporation Use of heat shock protein inhibitors for the treatment of neurodevelopmental disorders
IL302081A (en) * 2020-10-14 2023-06-01 Ranok Therapeutics Hangzhou Co Ltd Methods and compositions for targeted protein degradation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010060937A2 (en) 2008-11-28 2010-06-03 Novartis Ag Hsp90 inhibitor combinations
WO2010124283A2 (en) 2009-04-24 2010-10-28 The Jackson Laboratory Methods and compositions relating to hematologic malignancies
WO2011022440A2 (en) 2009-08-17 2011-02-24 Memorial Sloan-Kettering Cancer Center Heat shock protein binding compounds, compositions, and methods for making and using same

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303652B1 (en) * 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
EP1937258A2 (en) 2005-09-23 2008-07-02 Conforma Therapeutics Corporation Anti-tumor methods using multi drug resistance independent synthetic hsp90 inhibitors
US8277807B2 (en) * 2006-10-12 2012-10-02 Astex Therapeutics Limited Pharmaceutical combinations
WO2008100985A2 (en) * 2007-02-15 2008-08-21 Novartis Ag Combination of lbh589 with other therapeutic agents for treating cancer
WO2008114812A1 (ja) * 2007-03-19 2008-09-25 Kyowa Hakko Kirin Co., Ltd. Jak阻害剤
CN101808516B (zh) * 2007-07-30 2013-08-28 阿迪生物科学公司 作为mek抑制剂的包括多晶型物的n-(芳氨基)磺酰胺衍生物和组合物、其使用方法和制备方法
US20100310563A1 (en) * 2007-11-30 2010-12-09 Bumm Thomas G P Methods for treating induced cellular proliferative disorders
US20110224223A1 (en) * 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
WO2010020618A1 (en) * 2008-08-18 2010-02-25 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Susceptibility to hsp90-inhibitors
EP2443123B1 (en) * 2009-06-15 2017-04-05 Rigel Pharmaceuticals, Inc. Small molecule inhibitors of spleen tyrosine kinase (syk)
US20110118298A1 (en) * 2009-11-13 2011-05-19 Infinity Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
EA031737B1 (ru) * 2010-06-03 2019-02-28 Фармасайкликс, Инк. Применение ингибиторов тирозинкиназы брутона (btk) для лечения лейкоза и лимфомы
EP2714038A1 (en) * 2011-05-24 2014-04-09 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with mtor/pi3k inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010060937A2 (en) 2008-11-28 2010-06-03 Novartis Ag Hsp90 inhibitor combinations
WO2010124283A2 (en) 2009-04-24 2010-10-28 The Jackson Laboratory Methods and compositions relating to hematologic malignancies
WO2011022440A2 (en) 2009-08-17 2011-02-24 Memorial Sloan-Kettering Cancer Center Heat shock protein binding compounds, compositions, and methods for making and using same

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Caldas Lopes et al, PNAS (2009), vol. 106, no. 20, pp. 8368-8373.
Grover et al, BMC Bioinformatics (2011.02.15.), vol. 12, pp. 1-13.
Jason P Holland et al, PLOS ONE (2010), vol. 5(1), e8859, pp. 1-11.
John J Wright et al, Clinical Cancer Research (2010.08.03. online published), vol. 16, no. 16, pp. 4094-4104.
Tony Taldone et al, Bioorganic and Medicinal Chemistry (2011.04.15.), vol. 19, no. 8, pp. 2630-2614.
Zhang et al, Molecular Cancer Therapeutics (2006), vol. 5, no. 5, pp. 1256-1264.

Also Published As

Publication number Publication date
WO2012149493A3 (en) 2014-05-08
MX2013012183A (es) 2014-05-27
AU2017272303A1 (en) 2018-01-04
CN103998935A (zh) 2014-08-20
KR20190112839A (ko) 2019-10-07
WO2012149493A2 (en) 2012-11-01
JP6375345B2 (ja) 2018-08-15
EA201391587A1 (ru) 2014-08-29
EP2701747A2 (en) 2014-03-05
NZ618062A (en) 2016-04-29
JP6363502B2 (ja) 2018-07-25
JP2017036288A (ja) 2017-02-16
KR102196424B1 (ko) 2020-12-30
JP2014523516A (ja) 2014-09-11
KR20140059757A (ko) 2014-05-16
US20140315929A1 (en) 2014-10-23
CA2833390A1 (en) 2012-11-01
AU2020200262A1 (en) 2020-02-06
AU2012249322B2 (en) 2018-01-04
EP2701747A4 (en) 2015-04-01
CN103998935B (zh) 2018-10-16
AU2012249322A1 (en) 2013-12-12
US20220074941A1 (en) 2022-03-10
JP2018153194A (ja) 2018-10-04
CN109498812A (zh) 2019-03-22
BR112013027448A2 (pt) 2020-09-01

Similar Documents

Publication Publication Date Title
KR102027448B1 (ko) Hsp90 병용요법
Kohsaka et al. STAT3 inhibition overcomes temozolomide resistance in glioblastoma by downregulating MGMT expression
JP6047149B2 (ja) 併用の医薬組成物およびその使用
Valvezan et al. IMPDH inhibitors for antitumor therapy in tuberous sclerosis complex
KR20230092962A (ko) 암, 자가면역 장애, 및 염증성 장애의 치료에서의 n-미리스토일 트랜스퍼라제(nmt) 억제제의 용도
WO2023093840A1 (en) Use of wee1 kinase inhibitors in the treatment of cancer
Frett et al. Therapeutic Melting Pot of Never in Mitosis Gene A Related Kinase 2 (Nek2): A Perspective on Nek2 as an Oncology Target and Recent Advancements in Nek2 Small Molecule Inhibition: Miniperspective
Zemanova et al. Chk1 inhibition significantly potentiates activity of nucleoside analogs in TP53-mutated B-lymphoid cells
EP3427736B1 (en) Activators and therapeutic applications thereof
US20050171182A1 (en) Methods and compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
Gao et al. Regulation of Eukaryotic Translation Initiation Factor 4E as a Potential Anticancer Strategy
HK40006457A (en) Hsp90 combination therapy
Wang et al. A modified nucleoside O6-methyl-2′-deoxyguanosine-5′-triphosphate exhibits anti-glioblastoma activity in a caspase-independent manner
Korycka-Wołowiec et al. Pharmacodynamic considerations of small molecule targeted therapy for treating B-cell malignancies in the elderly
Diehl Investigation of the Kinome in Pancreatic Ductal Adenocarcinoma
Villarreal Exploring novel roles of metabolic enzymes MTHFD2 and PFKFB3 in cancer genome stability and their potential as anticancer therapeutic targets
Stern et al. Targeting CDK12/13 Drives Mitotic Arrest to Overcome Resistance to KRASG12C Inhibitors
Ravikrishnan Targeted Therapies for High-Risk Chronic Lymphocytic Leukemia
Ladds p53 transcriptional activity as a tool to uncover novel and diverse druggable targets in cancer
Robb Evaluation of Aminopyrazole Analogs as Cyclin-Dependent Kinase Inhibitors for Colorectal Cancer Therapy
Heppler Identifying Therapeutic Vulnerabilities in Cancers Driven by the Oncogenic Transcription Factor STAT3
Lonetti Study of PI3K/Akt signaling pathway as potential molecular target for T-cell acute lymphoblastic leukemia (T-ALL) treatment: pan-inhibition of PI3K catalitic isoforms as better therapeutic approach
Herman Manipulation of Kinase Signaling in Chronic Lymphocytic Leukemia: The Effect on Disease State
Goldstein The role of Hsp90 in B cell receptor signaling and novel combinatorial therapies for ABC DLBCL
Sherman Transcriptional Regulation of B Cell Development by CRTC2

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20230926

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20230926